# A Study to Evaluate the Pharmacokinetics and Safety Between HCP2303 and Co-administration of Each Component in Healthy Volunteers Under Fed Conditions

> **NCT06357910** · PHASE1 · COMPLETED · sponsor: **Hanmi Pharmaceutical Company Limited** · enrollment: 34 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** HCP2303
- **DRUG:** RLD2302
- **DRUG:** RLD2102

## Key facts

- **NCT ID:** NCT06357910
- **Lead sponsor:** Hanmi Pharmaceutical Company Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-05-17
- **Primary completion:** 2024-07-01
- **Final completion:** 2024-07-01
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2024-07-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06357910

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06357910, "A Study to Evaluate the Pharmacokinetics and Safety Between HCP2303 and Co-administration of Each Component in Healthy Volunteers Under Fed Conditions". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06357910. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*